$NVO

This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday - Chewy (NYSE:CHWY), Novo N

Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight, maintaining a $40 target. JP Morgan downgraded Chewy (CHWY) to Neutral, cutting the target to $24. UBS downgraded NuScale Power (SMR) to Sell, lowering the target to $6. JP Morgan also downgraded Atmos Energy (ATO) to Neutral, reducing the target to $180.

Original reporting
Published Sep 11, 2026, 1:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NVO
Bearish
medium confidence
Mentioned
$NVO · $CHWY · $SMR · $ATO
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$NVOBearishMed
01

Why it matters

These downgrades reflect revised expectations and could influence short-term price action.

02

Market read

Four U.S.-listed companies received rating downgrades, suggesting a modest bearish tilt in the market.

03

What to watch

Potential upcoming product launches or contract wins not covered in the downgrade notes.

Relevance 7/10Novelty 7/10Timing: today

Background

Analyst rating changes are common after earnings releases or guidance updates.

Company-level read

Ticker impact

$NVOBearishMedium confidence
Context

Morgan Stanley downgraded Novo Nordisk to Underweight and kept a $40 price target.

Expected impact

Potential short-term decline of 2-4%

Evidence & confidence

Downgrade signals weaker outlook; target below current price.

$CHWYBearishMedium confidence
Context

JP Morgan cut Chewy's price target to $24 and moved rating to Neutral.

Expected impact

Possible 3-5% drop in near term.

Evidence & confidence

Lower target and rating downgrade suggest weaker earnings expectations.

$SMRBearishMedium confidence
Context

UBS downgraded NuScale Power to Sell with a $6 target.

Expected impact

Likely 4-6% slide.

Evidence & confidence

Significant target reduction and sell rating indicate heightened risk.

$ATONeutralLow confidence
Context

JP Morgan moved Atmos Energy to Neutral and cut target to $180.

Expected impact

Flat to slight dip, 1-2% range.

Evidence & confidence

Rating change modest; target still above current price.

Market effects

Healthcare and consumer discretionary sectors may see modest pressure from analyst downgrades.

U.S. equities could experience slight pullback in the morning session.

Limited; primarily affects U.S.-listed stocks.

Counterpoint

Some investors may view the downgrades as overreactions and look for buying opportunities.

Key entities

  • Morgan Stanley

    Provided downgrade for Novo Nordisk.

  • JP Morgan

    Downgraded Chewy and Atmos Energy.

  • UBS

    Downgraded NuScale Power.

Related articles

$SMRMed

SMR Stock Slides As UBS Downgrade Triggers Legal Scrutiny

NuScale Power (NYSE: SMR) shares fell 7.17% after UBS downgraded the stock to Sell with a $6 price target, citing concerns over competitive edge, weak customer traction, and cash burn. Pomerantz LLP launched an investigation into potential securities fraud. The company reported $31.5M in revenue, significant losses, and negative cash flow. SMR's valuation is high with an enterprise value near $2.49B and a price-to-sales ratio above 300.

$CEGHighAI 8/10

Has Nuclear Energy Trade Seen Its Bottom? What Jan Van Eck Sees In The Constellation-Google Deal

Jan van Eck, CEO of Van Eck Funds, suggests the nuclear energy sector may have bottomed out, citing a 20-year deal between Constellation Energy (CEG) and Google (GOOG, GOOGL) for 890 MW of nuclear capacity, backed by $4.3B in investment. The deal sparked a rally in nuclear stocks, with CEG up 12% and others like VST, TLN, OKLO, SMR, and NNE also gaining. Van Eck believes supporting AI infrastructure, like nuclear power, could rebound, though prediction markets see low odds for this year.

$NVOLow

Weight-loss drugs show signs of slowing biological aging, say drugmakers

Novo and Eli Lilly presented findings at a conference suggesting their GLP-1 weight-loss drugs may slow biological aging. Novo's semaglutide and Lilly's tirzepatide showed reductions in biological age of 2-4 years in overweight or diabetic patients. Both drugs are among the best-selling globally, with Lilly's tirzepatide generating $36B in 2023 revenue. The studies used proteomic and epigenetic clocks to measure aging effects.